Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Syndrome

Polycystic Ovary Syndrome

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

All Drugs and Chemicals

Hormones

Hormone Antagonists

IV administration of kisspeptin 112-121; 24-hour infusion. IV administration of GnRH; up to one bolus.

IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin

kisspeptin 112-121

GnRH

Study Coordinator

Stephanie B Seminara, MD

The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).

Assignment: All study subjects will undergo the same interventions. Baseline LH secretion patterns of individuals with PCOS will be compared to their LH secretion patterns while receiving a kisspeptin infusion.

Delivery of Interventions:

* Prior to the inpatient study visit, the subjects will undergo a review of their medical history, physical exam, and screening laboratories.
* On the day of the study, the subjects will have an intravenous (IV) line placed and

  * Undergo up to q10 min blood sampling x 36 hours
  * Receive an infusion of kisspeptin x 24 hours
  * Receive up to two kisspeptin IV boluses
  * Receive up to one gonadotropin-releasing hormone (GnRH) IV bolus

Dampening the Reproductive Axis With Continuous Kisspeptin

Average change in LH pulse frequency before and during kisspeptin infusion

Average change in LH pulse amplitude before and during kisspeptin infusion

Stephanie B. Seminara, MD

Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine

Nutritional and Metabolic Diseases

Skin and Connective Tissue Diseases

Heart and Blood Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Rare Diseases

Diabetes Mellitus

Uterine Cervical Neoplasms

Breast Neoplasms

Hypertension

Lung Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Endometrial Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Neoplasms

Uterine Diseases

Ovarian Cancer

Ovarian Epithelial Cancer

Xiu Qiu, PhD

The Guangzhou Women's Health Cohort Study aims to explore the health trajectory and factors contributing to the health of women aged 35-64 in Guangzhou. Based on multiple population health registration data platforms, data of the cohort will provide information about the health of women across the lifespan, facilitating the decision-making process by local government . The cohort is progressing steadily, and the goal is to build a large women cohort covering 11 administrative districts of Guangzhou with a scale of 1 million by 2030.

Guangzhou Women's Health Cohort Study (GWHCS)

Guangzhou Women and Children's Medical Center

Head of the Department of Women's Health

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dampening the Reproductive Axis With Continuous Kisspeptin	NCT05971849	Reproductive Di... PCOS Polycystic Ovar...	kisspeptin 112-... GnRH	18 Years - 45 Years	Massachusetts General Hospital
Guangzhou Women's Health Cohort Study (GWHCS)	NCT05506800	Cervical Cancer Breast Cancer Lung Cancer Colorectal Canc... Endometrial Can... Ovarian Cancer Hypertension Diabetes Reproductive Di...		35 Years - 64 Years	Guangzhou Women and Children's Medical Center
Dampening the Reproductive Axis With Continuous Kisspeptin	NCT05971849	Reproductive Di... PCOS Polycystic Ovar...	kisspeptin 112-... GnRH	18 Years - 45 Years	Massachusetts General Hospital

Spots Global Cancer Trial Database for reproductive disorder